Sudhir Srivastava, PhD, MPH
Sudhir Srivastava, PhD, MPH
National Cancer Institu
Rockville, MD, USA
Dr. Srivastava is Senior Scientific Officer and Chief of the Cancer Biomarkers Research Group in the Division of Cancer Prevention, National Cancer Institute. He joined the National Cancer Institute in 1988. Since 1990, he has served as program director in the Division of Cancer Prevention and focused his responsibility in developing molecular signatures of cancer cells for cancer detection research programs with primary emphasis on cancer screening, early detection, risk assessment and informatics.
Dr. Srivastava is an internationally recognized leader in cancer biomarker research. He is best known for his seminal contributions to improving systems approach to biomarker discovery, development and validation. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network (EDRN; www.cancer.gov/edrn ), a flagship program at the National Cancer Institute, National Institutes of Health. Under his leadership the network has begun translating biomarkers into clinical tests for early detection and diagnosis, risk assessment, and prognosis. He has spearheaded the role of chemical sciences in oncology by establishing the NCI’s Alliance of Glycobiologists (glycomics.cancer.gov) to study the structure-function relationship of glycans and biomarkers in cancer detection and diagnosis. He has played a key role in conceptualizing and implementing informatics infrastructure for the EDRN in collaboration with NASA (Jet Propulsion Laboratory), a model collaboration being followed elsewhere in NIH.
Dr. Srivastava is best known for his work on developing medical guidelines on the diagnosis of Hereditary Non-polyposis Colorectal Cancer (HNPCC). He played a pivotal role in the development of the Bethesda Guidelines for diagnosing HNPCC, which is in clinical practice world-wide. He has received several honors and awards and is a member of a number of scientific committees world-wide. In 1995, he was elected to the American Joint Committee on Cancer (AJCC) which is responsible for developing staging criteria for cancers for worldwide use and currently serves on the AJCC Executive Committee. He has been a visiting Professor at several medical and academic institutions, and has delivered several inaugural and keynote addresses.
He is founding Editor-in Chief of the journal Cancer Biomarkers, published by the IOS press and serves as Associate Editors and reviewers for several internally know journals. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. He has edited several monographs and five book: Early Detection of Cancer: Molecular Markers, published by the Futura Publishing Company in 1995 and Molecular Pathology of Cancer, published by IOS Press, Amsterdam in 1999; Informatics in Proteomics (2005) published by Francis and Taylor, New York; Translational Pathology of Early Cancer (2012), published by the IOS Press and Biomarkers in Cancer Screening and Early Detection (2017) published by Wiley, New York. Among his other editorial accomplishments, he served as the Editor-in-Chief for the journal the journal, Disease Markers for more than 10 years and brought this journal to scientific excellence.
Dr. Srivastava has received numerous NCI and NIH awards for his leadership in biomarker research and received a Team Science Award for Informatics by the Jet Propulsion Laboratory, NASA for his visionary and innovative use of NASA Data System Technologies in biomedical science. In 2016, he received a Cancer Prevention Distinguished Alumni Award for his accomplishments and mentoring of fellows and a Distinguished Service Award by the American Association of Pancreatology for promoting research on pancreatic cancer. In 2017, he was awarded a Distinguished Scientist Award which recognizes a scientist for distinguished scientific achievements in the field of clinical and translational proteomics. He was featured in Wired magazine in August 2003 for his leadership in cancer diagnostics. He has been planning and managing comprehensive extramural scientific programs for more than 26 years. Through these years, a number of organizational changes have taken place at the National Cancer Institute with revised missions and goals to meet the expectations of cancer patients, advocacy groups, and the members of the US Congress. In 2016, he was invited to brief the US Congress on progress made on biomarkers for cancer early detection. He has successfully managed several mission-critical goals of the National Cancer Institute at various fronts including: conceptual, infrastructure, dependency linkage, and coordination among various federal, academic and private sector constituents. The launching of the Cancer Biomarkers Research Program required building partnerships with various NCI programs, professional societies and demanded professional leadership in planning, developing and presenting concepts before various advisory boards, identifying and integrating key issues affecting organization including various advocacy groups, technological, social and other administrative factors.
Dr. Srivastava received his PhD in biological science from Banaras Hindu University in 1977. Subsequently, he received his MS degree in Computer Science from the Virginia Commonwealth University in 1987 and a MPH degree from the Johns Hopkins University in 1997. He did postdoctoral work at the University of Osaka, Japan; the University of California at San Francisco; and the University of Arizona, Tucson.